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Hua-shan Wang1†, Joanne Toh1†, Patrick Ho1, Murni Tio1, Yi Zhao2 and Eng-King Tan1,3,4*Abstract
Mutations of VPS35, a component of the retromer complex have been associated with late onset familial Parkinson’s
disease. The D620N mutation in VPS35 appears to be most prevalent, however, P316S was found in two cases within
the same family and a control, whereas L774M was identified in 6 cases and 1 control. In vivo evidence of their
pathogenicity is lacking. Here we investigated the in vivo effects of P316S, D620N and L774M using Drosophila as a
model. We generated transgenic human VPS35-expressing mutations and demonstrated that VPS35 D620N transgenic
flies led to late-onset loss of TH-positive DA neurons, poor mobility, shortened lifespans and increased sensitivity to
rotenone, a PD-linked environmental toxin, with some of these phenotypes observed for P316S but not in L774M
transgenic flies. We conclude that D620N and to a smaller extent P316S are associated with pathogenicity in PD.
Keywords: Parkinson’s disease, Drosophila, VPS35, Retromer complexIntroduction
Parkinson’s disease (PD) is a neurodegenerative disorder
that affects 1% of the aging population. It is characterized
by the loss of midbrain dopaminergic (DA) neurons in
the substantia nigra region as well as accumulation of
Lewy body aggregates. Although PD has been studied
extensively, the molecular etiology is still unknown,
with many trying to unravel the genetic determinants
of PD [1]. VPS35 encodes for a subunit of the retromer,
a coat-like protein complex that is involved in the
recycling of membrane proteins. The retromer complex
helps to guide protein sorting from the endosome-
lysosome degradation pathway retrogradely to the Golgi
apparatus and VPS35 functions as a platform for binding
to other subunits (VPS26 and VPS29) with its distal ends
in retromer assembly [2,3].
Recently, a number of reports determined a link between
mutations in VPS35 and familial late-onset PD [4,5].
Successive studies showed that D620N mutation in
VPS35 is the most prevalent and found to be associated
with autosomal dominant PD in Caucasian and Japanese* Correspondence: gnrtek@sgh.com.sg
†Equal contributors
1National Neuroscience Institute, 11 Jalan Tan Tock Seng, 308433 Singapore,
Singapore
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unless otherwise stated.families but not in the Han Chinese population [6-9].
There are reports on other single mutations such as
L774M and P316S but their pathogenicity remains
unclear. P316S was found in two cases within the same
family however, with a control subject also identified
with the same mutation, genetic evidence for the patho-
genicity of P316S remains unconvincing. L774M was
identified in 6 cases and 1 control, hence the inconclusive
evidence [5,10].
In flies, VPS35 was found to be involved in a number
of physiological functions. Knockdown of VPS35 led to
the inhibition of scavenger receptor endocytosis and
VPS35 mutation resulted in the overproliferation and
excessive differentiation of haemocytes, suggesting that
it might have a tumor suppressor function. Also, there is
likely a conserved function of VPS35 playing a role in
endocytic trafficking [11]. In addition, VPS35 was shown
to act in the same pathway with Rab9 to control tracheal
length by positively regulating the luminal deposition of
Serp, a specific cargo for the retromer-dependent endocytic
trafficking [12]. Macleod et al., demonstrated that overex-
pression of VPS35 rescues dopaminergic neuronal loss and
reduced lifespan caused by expression of LRRK2 G2019S
in dopaminergic neurons, showing interaction between
VPS35 and LRRK2 [13].
To date, there is limited in vivo evidence of pathogenicity
of VPS35 mutations reported in single patients. To addresstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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we investigated the pathogenicity of three reported VPS35
mutations, P316S, D620N and L774M in vivo. We showed
evidence that D620N is the most pathogenic mutation in
VPS35 followed by P316S, and that these mutations in
VPS35 are linked to PD.
Materials and methods
Experiments carried out adhered to ethical standards of the
Research Center with regards to non-human experiments.
Fly stocks
The following flies were used in this study: dopa decarb-
oxylase (ddc)-GAL4 and yellow white (yw) (Bloomington
Drosophila Stock Center). Human VPS35-expressing flies
were created by generating transgenic human VPS35 wild
type or mutant (P316S, D620N and L774M) cDNA con-
taining a Hemagglutinin (HA) tag at the C-terminus and
inserted into the pUAST-attB plasmid, which will allow
the UAS constructs to land into a chosen attP site in the
fly genome during microinjection. Constructs were then
sent for microinjection into Drosophila embryos (Best-
Gene). Flies were raised on standard yeast-cornmeal-agar
medium at 25°C with 12-hour light and dark cycle.
Western blot, immunofluorescence and confocal
microscopy
Protein was extracted from fly head homogenates and
equal amounts of protein from the various genotypes
were resolved by SDS-PAGE. HA-tagged VPS35 was
detected using mouse anti-HA (1:1000, Santa Cruz).
Flies were aged to day 20 and 60 after eclosion, before
fly brains were dissected, fixed and stained according to
published protocols [14]. Brains were probed with rabbit
anti-tyrosine hydroxylase (1:500, Sigma-Aldrich) and
mouse anti-HA (1:200, Santa Cruz).
Climbing, lifespan assays and rotenone treatment
Climbing assay was performed as described previously
[15]. To determine adult lifespan, 100 flies from each
genotype under the direction of ddc-GAL4 were main-
tained on standard media. Newly eclosed adult flies
were transferred into vials containing fresh media every
3 days and mortality was scored daily. Age-matched
ddc-GAL4/+flies used as controls. In rotenone-treated
flies, flies were fed with cornmeal-agar medium containing
500 μM rotenone (Sigma), which was first dissolved in
DMSO, immediately after eclosion and during entire
experimental period.
Statistical analysis
Quantitative data are expressed as mean ± SEM, unless
otherwise stated. Statistical significance for climbing assay
and differences in the number of TH-positive DA neuronswere analyzed using one-way Anova with Bonferroni’s
post hoc test, unless otherwise stated. Lifespan assay was
analyzed with Log-rank test.Results
VSP35 D620N promotes DA neurodegeneration and loss
of locomotor activity
To study the pathogenic effects of VPS35 mutants in vivo,
we generated the following HA tagged transgenic flies:
wild type VPS35 as control, and mutant VPS35 flies,
P316S, D620N and L774M. They were verified via im-
munostaining and immunoblot that the VPS35 from
the different variants were expressed and in comparable
amounts (Additional file 1: Figure S1).
ddc-GAL4 flies, commonly used in drosophila PD
research was used here for the overexpression of the
various VPS35 transgenes in TH-positive DA neurons
and to examine the gain-of-function effects of mutant
VPS35 [16]. We first studied if DA neuronal integrity
was affected, since this is a characteristic of PD patients,
by comparing the number of TH-positive DA neurons (six
clusters in each brain hemisphere). There was no apparent
difference at 20 days after eclosion across all genotypes
(Figure 1A) but in aged 60 days old flies, we saw a sig-
nificant loss of TH-positive DA neurons in the PPL1
clusters of VPS35 D620N mutant flies (p < 0.05) compared
to age matched wild type and control (ddc-GAL4/+) flies
(Figure 1B, C). Interestingly, there was also significant
difference between PPL1 clusters of control and wild
type VPS35 flies (p < 0.05) (Figure 1B).
As DA neuronal loss has been linked to locomotor
dysfunction, we compared the mobility of the various
genotypes. At 20 and 40 days post eclosion, we observed a
significant difference in climbing ability when comparing
control flies to wildtype, P316S and D620N flies (p < 0.05)
(Figure 1D). At 60 days post eclosion, there was a
marked reduction in climbing abilities for all genotypes
except L774M transgenic flies, with the climbing scores
for VPS35 P316S and D620N flies significantly lower
(p < 0.05) compared to age matched control and VPS35
wild type flies (Figure 1D). This correlated with the
significant loss of DA neurons in VPS35 D620N mutant
flies at 60 days. Interestingly, L774M transgenic flies
displayed robust climbing even after 60 days of aging.
There was a significant decrease (p < 0.05) in the median
lifespan of D620N flies (63 days) compared to wild type
and control flies (70 days) (Figure 1E).Rotenone treatment further exacerbated the
pathogenicity of D620N VPS35 variant in DA neuron
degeneration
We challenged the various transgenic VPS35-expressing
flies with rotenone to examine their relative susceptibility
Figure 1 Expression of VPS35 pathogenic variant D620N in flies result in DA neuronal degeneration and locomotive dysfunction. (A, B)
Bar graphs show number of TH-positive DA neurons in flies at 20 and 60 days after eclosion (n = 3, cohort of 10). (C) Representative confocal images
of whole mount brains 60 days after eclosion of VPS35 wild type, P316S and D620N flies with magnified views of PPL1 cluster (boxed on the right).
(D) Bar graph shows age-dependent climbing scores of female flies at different days after eclosion. Percentage of flies that reached the top of the
column after 1 min were counted (n = 3, cohort of 20). (E) Survival curves were plotted as percentage of living flies. (n = 3, cohort of 100).
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response to a PD-linked environmental toxin. We observed
a faster loss (15 days) of DA neurons in the PPL1 clusters
of rotenone-treated flies expressing VPS35 P316S or
D620N flies compared to age-matched control flies.
Accelerated loss of TH-positive DA neurons was also
observed in the PPL2 cluster of VPS35 P316S and
D620N flies (p < 0.05) (Figure 2). Again, we did not find
any loss of TH-positive DA neurons in flies expressing
VPS35 L774M as rotenone treatment failed to enhance
any loss of TH-positive DA neurons. These results suggest
that D620N VPS35 flies are highly susceptible to rotenone
DA neurodegeneration.Discussion
VPS35 is a component of the retromer complex recently
linked to autosomal dominant late onset PD and in vivo
evidence of pathogenicity of VPS35 mutations in single
patient is lacking. Here, we characterized three reported
variants of VPS35, P316S, D620N and L774M, in flies and
provided in vivo evidence of the pathogenicity of VPS35
D620N mutation. We demonstrated that the expression of
VPS35 D620N and to a smaller extent P316S, lead to the
loss of TH-positive DA neurons, locomotor dysfunction
and reduced lifespan.
The C-terminal amino acid residues 307 – 796 form
an α-solenoid fold that fits into the metal-binding site of
Figure 2 Exposure of VPS35 P316S and D620N mutant flies to rotenone accelerates DA neuronal loss. (A) Bar graph shows the
quantification of the number of DA neurons in different clusters of various fly species 15 days after rotenone treatment (n = 3, cohort of 10).
(B) Representative confocal images showing TH-positive DA neurons in the PPL1 cluster of rotenone treated fly species in VPS35 wild type,
P316S and D620N flies.
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might interfere with the interaction and assembly with
VPS29, and disrupt retromer function in trafficking
proteins intracellularly [17,18]. D620N is at the region
where VPS35 binds not only to VPS29, but also accessory
proteins such as cation-independent mannose-6-phosphate
receptor (CI-MPR) and SNX1, whereby the former is
essential for efficient anterograde transport of soluble
hydrolases and also retrieval of mislocalized resident
Golgi proteins, and the latter implicated in sorting of
activated signaling receptors for lysosomal degradation
[19]. Zavodszky et al. found that unlike a complete
knockdown of VPS35 that eliminates retromer function,
the D620N mutation affects retromer function linked to
the WASH complex. They recently published findings
showing that D620N mutation in VPS35 destabilizes
the retromer-WASH complex interaction, resulting in
reduced endosomal localization of the WASH complex,
and that cells expressing the D620N VPS35 mutation
exhibited defects in autophagy [20]. Defects in autophagy
could be a contributor to PD pathogenesis as it may
aggravate pathologies associated with PD, such as mito-
chondrial abnormalities, protein aggregation, increased
reactive oxygen species and higher sensitivity to cell
death. These may have contributed to the more severe
phenotype observed in D620N flies. Although the precise
mechanism of retromer dysfunction in PD is unclear, one
report observed that the expression of VPS35 D620N ledto endosomal alterations and defects in trafficking, which
may partially explain its action in PD [21].
An interesting observation was the robust climbing of
L774M mutation that appeared to have a protective
effect during the climbing assay after flies were aged.
As the mutation is at the C-terminus of VPS35 and is part
of the binding region of VPS35 to VPS29, the mutation
may have modulated structural changes in VPS35 such
that it binds to VPS29 more efficiently. Another interest-
ing observation was the toxic effect of over-expressing
wild type VPS35, as we observed significant differences in
the number of TH-positive neurons between age matched
control and wild type flies as well as climbing abilities of
age matched control and wild type flies at 20 and 40 days
old. These results suggest that over-expressing wild type
VPS35 alone causes the loss of DA neurons, and impairs
locomotion even though Macleod and colleagues observed
that the over-expression of wild type VPS35 rescued DA
neuronal loss and reduced life span caused by LRRK2
G2019S expression in DA neurons [13]. In addition, the
over-expression of D620N and P316S mutations aggravate
this effect, which is consistent with the dominant nature
of these mutations.
In a recent study by Tsika and colleagues, the common
VPS35 D620N mutation did not compromise the protein
stability, localization to endosomal and lysosomal vesicles,
or the vesicular sorting of retromer cargo in rodent primary
neurons or patient-derived human fibroblasts, suggesting
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of D620N VPS35 induced marked degeneration of substan-
tia nigra dopaminergic neurons and axonal pathology in a
rat model, implying that dominant VPS35 mutations lead
to neurodegeneration in PD, which is similar to our results
in flies [22].
We observed that the pathogenic process caused by
single mutations of D620N and P316S can be exacerbated
by rotenone, an environmental mitochondrial complex I
inhibitor that has been linked to PD. Other findings have
shown that the retromer complex regulates the transport
of mitochondrial-anchored protein ligase to peroxisomes
and that enhanced VPS35 expression protects dopamin-
ergic cells against mitochondrial stress, suggesting that
there might be a connection between VPS35 and patho-
genesis of PD via mitochondrial stress [23,24].
Our study in characterizing the various VPS35 mutations
will contribute to the understanding of VPS35-induced
PD, with in vivo confirmation of the pathogenicity VPS35
D620N mutation. Further functional and genetic studies
can be carried out to resolve the underlying mechanisms
of VPS35 in PD, in addition to studying the interactions
between VPS35 and other PD associated genes, which
might provide important insights in the identification of
more effective drug or molecular therapeutic targets for
PD patients with VPS35 mutations.Additional file
Additional file 1: Figure S1. HA-tagged VPS35 transgenes tested for
expression and protein levels. (A) Immunostaining of whole-mount adult fly
brains expressing wild type or mutant human VPS35 in TH + neurons by
overexpressing HA-tagged VPS35 variants in TH + neurons using ddc-GAL4.
Top row: anti-HA. Middle row: anti-TH. Bottom row: Merged images of
anti-HA (green) and anti-TH (red). (B) An anti-HA immunoblot of adult brain
lysates prepared from control (elav-GAL4/+) or transgenic flies expressing
the various VPS35 variants (elav-GAL4 > VPS35 variants).Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WHS conceived and designed the study. WHS, JT and PH participated in carrying
out the experiments. WHS and JT participated in analyzing the data. JT and ET
drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgements
National Medical Research Council, Singapore Millennium Foundation,
Singapore General Hospital, and Duke NUS Graduate School of Medicine.
Supported by the Singapore National Research Foundation under its
Translational and Clinical Research Flagship Programme and administered by
the Singapore Ministry of Health’s National Medical Research Council.
Author details
1National Neuroscience Institute, 11 Jalan Tan Tock Seng, 308433 Singapore,
Singapore. 2Department of Clinical Research, Singapore General Hospital,
169856 Singapore, Singapore. 3Department of Neurology, Singapore General
Hospital, 169856 Singapore, Singapore. 4Duke-NUS Graduate Medical School,
8 College Road, 169857 Singapore, Singapore.Received: 11 July 2014 Accepted: 24 September 2014References
1. Tan EK, Skipper LM: Pathogenic mutations in Parkinson disease. Hum Mutat
2007, 28(7):641–653.
2. Skinner C, Seaman M, Skinner C, Seaman M: The role of retromer in
neurodegenerative disease. In Research and Perspectives in Alzheimer’s
Disease. Edited by St. George-Hyslop PH, Mobley WCC, Yves C. Heidelberg:
Springer Berlin; 2009:125–140.
3. Bonifacino JS, Hurley JH: Retromer. Curr Opin Cell Biol 2008, 20(4):427–436.
4. Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN,
Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N,
Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki
T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F,
Brücke T, Poewe W, Auff E, Trenkwalder C, Rost B, et al: A mutation in
VPS35, encoding a subunit of the retromer complex, causes late-onset
Parkinson disease. Am J Hum Genet 2011, 89(1):168–175.
5. Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ,
Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL,
Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO,
Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T,
Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, et al: VPS35
mutations in Parkinson disease. Am J Hum Genet 2011, 89(1):162–167.
6. Ando M, Funayama M, Li Y, Kashihara K, Murakami Y, Ishizu N, Toyoda C,
Noguchi K, Hashimoto T, Nakano N, Sasaki R, Kokubo Y, Kuzuhara S, Ogaki K,
Yamashita C, Yoshino H, Hatano T, Tomiyama H, Hattori N: VPS35 mutation
in Japanese patients with typical Parkinson’s disease. Mov Disord 2012,
27(11):1413–1417.
7. Guo JF, Sun QY, Lv ZY, Yu RL, Li K, Zhang YH, Tian JY, Xia K, Yan XX, Tang BS:
VPS35 gene variants are not associated with Parkinson’s disease in the
mainland Chinese population. Parkinsonism Relat Disord 2012, 18(8):983–985.
8. Lesage S, Condroyer C, Klebe S, Honoré A, Tison F, Brefel-Courbon C, Dürr A,
Brice A, French Parkinson’s Disease Genetics Study Group: Identification of
VPS35 mutations replicated in French families with Parkinson disease.
Neurology 2012, 78(18):1449–1450.
9. Sheerin UM, Charlesworth G, Bras J, Guerreiro R, Bhatia K, Foltynie T, Limousin
P, Silveira-Moriyama L, Lees A, Wood N: Screening for VPS35 mutations in
Parkinson’s disease. Neurobiol Aging 2012, 33(4):838. e1-838.e5.
10. Sharma M, Ioannidis JPA, Aasly JO, Annesi G, Brice A, Bertram L, Bozi M,
Barcikowska M, Crosiers D, Clarke CE, Facheris MF, Farrer M, Garraux G,
Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori
N, Jeon BS, Jamrozik Z, Krygowska-Wajs A, Lesage S, Lill CM, Lin JJ, Lynch T,
Lichtner P, Lang AE, Libioulle C, Murata M, et al: A multi-centre
clinico-genetic analysis of the VPS35 gene in Parkinson disease
indicates reduced penetrance for disease-associated variants. J Med
Genet 2012, 49(11):721–726.
11. Korolchuk VI, Schütz MM, Gómez-Llorente C, Rocha J, Lansu NR, Collins SM,
Wairkar YP, Robinson IM, O’Kane CJ: Drosophila Vps35 function is
necessary for normal endocytic trafficking and actin cytoskeleton
organisation. J Cell Sci 2007, 120(24):4367–4376.
12. Dong B, Kakihara K, Otani T, Wada H, Hayashi S: Rab9 and retromer
regulate retrograde trafficking of luminal protein required for epithelial
tube length control. Nat Commun 2013, 4:1358.
13. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD,
MacCabe BD, Marder KS, Honig LS, Clark LN, Small SA, Abeliovich A: RAB7L1
interacts with LRRK2 to modify intraneuronal protein sorting and
Parkinson’s disease risk. Neuron 2013, 77(3):425–439.
14. Whitworth AJ, Theodore DA, Greene JC, Beneš H, Wes PD, Pallanck LJ:
Increased glutathione S-transferase activity rescues dopaminergic
neuron loss in a Drosophila model of Parkinson’s disease. Proc Natl Acad
Sci 2005, 102(22):8024–8029.
15. Wang C, Lu R, Ouyang X, Ho MWL, Chia W, Yu F, Lim KL: Drosophila
overexpressing parkin R275W mutant exhibits dopaminergic neuron
degeneration and mitochondrial abnormalities. J Neurosci 2007,
27(32):8563–8857.
16. Ng CH, Mok SZS, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM,
Yu F, Lim KL: Parkin protects against LRRK2 G2019S mutant-induced
dopaminergic neurodegeneration in Drosophila. J Neurosci 2009,
29(36):11257–11262.
Wang et al. Molecular Brain 2014, 7:73 Page 6 of 6
http://www.molecularbrain.com/content/7/1/7317. Hierro A, Rojas AL, Rojas R, Murthy N, Effantin G, Kajava AV, Steven AC,
Bonifacino JS, Hurley JH: Functional architecture of the retromer
cargo-recognition complex. Nature 2007, 449(7165):1063–1067.
18. Collins BM, Skinner CF, Watson PJ, Seaman MNJ, Owen DJ: Vps29 has a
phosphoesterase fold that acts as a protein interaction scaffold for
retromer assembly. Nat Struct Mol Biol 2005, 12(7):594–602.
19. Collins BM: The structure and function of the retromer protein complex.
Traffic 2008, 9(11):1811–1822.
20. Zavodszky E, Seaman MN, Moreau K, Jimenez-Sanchez M, Breusegem SY,
Harbour ME, Rubinsztein DC: Mutation in VPS35 associated with Parkinson’s
disease impairs WASH complex association and inhibits autophagy.
Nat Commun 2014, 5:3828.
21. Follett J, Norwood SJ, Hamilton NA, Mohan M, Kovtun O, Tay S, Zhe Y,
Wood SA, Mellick GD, Silburn PA, Collins BM, Bugarcic A, Teasdale RD: The
Vps35 D620N mutation linked to Parkinson’s disease disrupts the cargo
sorting function of retromer. Traffic 2014, 15(2):230–244.
22. Tsika E, Glauser L, Moser R, Fiser A, Daniel G, Sheerin UM, Lees A, Troncoso JC,
Lewis PA, Bandopadhyay R, Schneider BL, Moore DJ: Parkinson’s disease-linked
mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet
2014, 23(17):4621–4638.
23. Braschi E, Goyon V, Zunino R, Mohanty A, Xu L, McBride HM: Vps35
mediates vesicle transport between the mitochondria and peroxisomes.
Curr Biol 2010, 20(14):1310–1315.
24. Bi F, Li F, Huang C, Zhou H: Pathogenic mutation in VPS35 impairs its
protection against MPP(+) cytotoxicity. Int J Biol Sci 2013, 9(2):149–155.
doi:10.1186/s13041-014-0073-y
Cite this article as: Wang et al.: In vivo evidence of pathogenicity of
VPS35 mutations in the Drosophila. Molecular Brain 2014 7:73.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
